Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.

To provide a new tool for the immunotherapy of human ovarian carcinoma, we constructed a fusion protein between interleukin-2 (IL-2) and the single-chain Fv (scFv) of MOV19, a monoclonal antibody directed against alpha-folate receptor (alpha-FR), known to be overexpressed on human nonmucinous ovarian carcinoma. This was accomplished by fusing the coding sequences in a single open reading frame and expressing the IL-2/MOV19 scFv chimera under the control of the murine immunoglobulin K promoter in J558L plasmacytoma cells. The design allowed the construction of a small molecule combining the specificity of MOV19 with the immunostimulatory activity of IL-2. This might improve the tissue penetration and distribution of the fusion protein within the tumor, reduce its immunogenicity, and avoid the toxicity related to the systemic administration of IL-2. The IL-2/MOV19 fusion protein was stable on purification from the cell supernatant and was biologically active. Importantly, this construct was able to target IL-2 onto the surface of alpha-FR-overexpressing tumor cells and stimulated the proliferation of the IL-2-dependent CTLL-2 cell line as well as that of human resting peripheral blood lymphocytes. In a syngeneic mouse model, IL-2/MOV19 scFv specifically targeted a-FR gene-transduced metastatic tumor cells without accumulating in normal tissues, due to its fast clearance from the body. Prolonged release of IL-2/MOV19 scFv by in vivo transplanted J558-EF6.1 producer cells protected 60% of mice from the development of lung metastases caused by an i.v. injection of a-FR gene-transduced tumor cells. Moreover, treatment with IL-2/MOV19 scFv, but not with recombinant IL-2, significantly reduced the volume of s.c. tumors. The pharmacokinetics and biological characteristics of IL-2/NMOV19 scFv might allow us to combine the systemic administration of this molecule with the adoptive transfer of in vitro retargeted T lymphocytes for the treatment of ovarian cancer, thereby providing local delivery of IL-2 without toxicity.

[1]  S. Canevari,et al.  Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. , 1998, Cancer research.

[2]  S. Gillies,et al.  Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. , 1997, Cancer research.

[3]  V. Brusic,et al.  Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA‐restricted cytotoxic T cells , 1997, International journal of cancer.

[4]  A. Eggermont,et al.  Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. , 1995, Journal of the National Cancer Institute.

[5]  G. Maass,et al.  Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  E. Atkinson,et al.  Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[7]  J. Xiang,et al.  Single‐chain antibody variable region‐targeted interleukin‐2 stimulates T cell killing of human colorectal carcinoma cells , 1994, Immunology and cell biology.

[8]  V. Zurawski,et al.  Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing. , 1994, Cancer research.

[9]  M. Colombo,et al.  Cytokine gene transduction in tumor cells: interleukin (IL)-2 or IL-4 gene transfer in human melanoma cells. , 1994, Natural immunity.

[10]  T. Blankenstein,et al.  Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  T. Clackson,et al.  Making antibody fragments using phage display libraries , 1991, Nature.

[12]  S. Canevari,et al.  Use of combination of monoclonal antibodies directed against three distinct epitopes of a tumor‐associated antigen: Analysis of cell binding and internalization , 1991, International journal of cancer.

[13]  H. P. Fell,et al.  Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab') with specificity for carcinomas and human IL-2. , 1991, Journal of immunology.

[14]  E. Gilboa,et al.  Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity , 1990, The Journal of experimental medicine.

[15]  W. Urba,et al.  Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.

[17]  K. Karjalainen,et al.  Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules , 1989, Nature.

[18]  S. Ménard,et al.  Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificity , 1987, International journal of cancer.

[19]  J. da Silva,et al.  Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. , 1985, Cancer research.

[20]  J. Marchalonis.  An enzymic method for the trace iodination of immunoglobulins and other proteins. , 1969, The Biochemical journal.

[21]  J. Becker,et al.  Immunocytokines: a new approach to immunotherapy of melanoma , 1997, Melanoma research.

[22]  F. Farzaneh,et al.  Ovarian tumour antigens as potential targets for immune gene therapy. , 1995, Gene therapy.

[23]  E. Seregni,et al.  Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. , 1995, European journal of cancer.

[24]  S. Canevari,et al.  Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MAb MOv18. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[25]  G. Bastert,et al.  Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. , 1991, European journal of cancer.

[26]  S. Stewart,et al.  Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered monoclonal antibodies , 1988 .